Core Viewpoint - 九州通 has successfully completed the restructuring investment plan for Aoyuan Meigu, acquiring its core assets for 706 million yuan, marking a strategic entry into the medical beauty sector [1][2][4] Group 1: Company Overview - Aoyuan Meigu, established in 1993 and formerly known as Hubei Jinhui, transitioned into the medical beauty industry after being acquired by Aoyuan Group in 2020 [2] - The company primarily focuses on bio-based fibers and medical beauty services, operating two high-end medical beauty hospitals with over 330,000 members and 80,000 active members annually [2] - In 2024, Aoyuan Meigu's medical beauty business is projected to generate 624 million yuan in revenue, accounting for 57% of total revenue [2] Group 2: Financial and Operational Challenges - Aoyuan Meigu has faced continuous operating losses and a debt crisis, leading to its stock being marked with "delisting risk warning" in 2023 [2] - The company was unable to repay due debts, prompting creditors to apply for restructuring in November 2024, which was approved by the court in December [3][4] Group 3: Strategic Implications for 九州通 - 九州通, as a leading private pharmaceutical distribution company, has built a comprehensive supply chain service platform and has been involved in the medical beauty sector for over 10 years [5][6] - The acquisition of Aoyuan Meigu allows 九州通 to establish a full-chain layout from upstream procurement to downstream service terminals, enhancing its competitive edge [6][7] - The domestic medical beauty market has surpassed 300 billion yuan, with an annual growth rate exceeding 18%, presenting significant opportunities for 九州通 to leverage its supply chain and improve profitability [6][7]

Core Viewpoint - The company is transforming its development momentum through the "Three New and Two Transformations" strategy, focusing on digital transformation, new retail, and new medical services to become the most professional health service provider in China and achieve its goal of becoming a century-old enterprise [1][7]. Digital Empowerment - The company has evolved from a grassroots pharmaceutical wholesaler to a technology-driven comprehensive service provider in the pharmaceutical industry, with a clear strategic path and implementation results in its digital transformation [1][2]. - The digital transformation includes collaboration across business, management, and logistics, with a focus on reducing costs and increasing efficiency [2][3]. - The company has achieved a significant reduction in logistics errors, with an error rate controlled at one in a million, enhancing both efficiency and quality [2]. Strategic Focus - The "Three New" strategy addresses the long-standing "two disconnections" in the industry by enhancing control over upstream products and establishing a new retail network for downstream channels [2][5]. - The company aims for new product-related sales to account for 20% of total revenue and 50% of gross profit in the next three years [3][5]. Medical Aesthetics Business - The company is accelerating its layout in the medical aesthetics sector, which has shown rapid growth, increasing from several million to several billion in scale [5][6]. - The medical aesthetics market is seen as a key profit growth point, driven by the aging population and rising consumer demand for beauty services [5][6]. Talent Strategy - The company has shifted its talent acquisition strategy, significantly increasing the recruitment of external senior talent to meet the demands of its strategic transformation [6][7]. - In 2023, the company introduced a "Three Transformations Talent Strategy," aiming to recruit over 300 senior talents annually [6]. Financial Performance - The company's sales revenue has grown from 21.185 billion in 2010 to 151.81 billion in 2024, with a compound annual growth rate of 15.10% [6]. - The net profit attributable to the parent company increased from 360 million in 2010 to 2.507 billion in 2024, with a compound annual growth rate of 14.88% [6].